

SKYEPHARMA PLC  
Form 6-K  
June 02, 2003

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June, 2003

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-  
\_\_\_\_\_

---

For Immediate Release

2 Ju

**SkyePharma PLC**

**Notification of Interests of Directors**

Edgar Filing: SKYEPHARMA PLC - Form 6-K

The Company was informed on 30 May 2003 by Mr Ian Gowrie-Smith, Executive Chairman of SkyePharma PLC, that on 30th May 2003 6,000,000 Ordinary Shares from his beneficial holding in the Company had been sold at a price of 53 pence per share to meet part of the obligations previously referred to in the Directors' Interests section of the Company's Annual Report. As a result of the transaction Mr Gowrie-Smith now has a beneficial interest in 19.3 million Ordinary Shares in the Company (subject to the proposed transfer previously disclosed in the Annual Report).

ends

<b>SkyePharma Plc</b> Peter Laing, Director of Corporate Communications	+ 44 (0) 20 7491 1777
<b>US Investor Relations</b> Sandra Haughton	+ 1 (212) 753-5780
<b>Buchanan Communications</b> Tim Anderson / Nicola How	+44 (0) 20 7466 5000

END

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill  
Title: Company Secretary

Date: June 2, 2003